fludarabine has been researched along with sjg 136 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delavault, P; Fegan, CD; Hambly, RM; Pepper, CJ; Thurston, DE | 1 |
| Delavault, P; Fegan, C; Hartley, JA; Lowe, H; Pepper, C; Thurieau, C; Thurston, DE | 1 |
2 other study(ies) available for fludarabine and sjg 136
| Article | Year |
|---|---|
The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Topics: Apoptosis; B-Lymphocytes; Benzodiazepines; Benzodiazepinones; Case-Control Studies; Caspase 3; Caspases; Cross-Linking Reagents; DNA Damage; DNA Repair; Enzyme Activation; Humans; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrroles; T-Lymphocytes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cross-Linking Reagents; DNA; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrroles; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine | 2007 |